Kura Oncology (NASDAQ:KURA) Insider Sells $79,485.54 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Brian Powl sold 8,891 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $79,485.54. Following the completion of the transaction, the insider directly owned 99,676 shares in the company, valued at $891,103.44. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kura Oncology Stock Up 4.0%

Shares of KURA opened at $9.20 on Thursday. The company has a market capitalization of $798.56 million, a P/E ratio of -4.07 and a beta of 0.32. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $19.73. The business’s 50 day simple moving average is $7.49 and its 200-day simple moving average is $6.68.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. As a group, sell-side analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming bought a new stake in shares of Kura Oncology in the 1st quarter valued at $48,000. Pallas Capital Advisors LLC bought a new stake in shares of Kura Oncology in the 1st quarter valued at $66,000. Tower Research Capital LLC TRC increased its position in shares of Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after buying an additional 9,958 shares in the last quarter. Flower City Capital bought a new stake in shares of Kura Oncology in the 1st quarter valued at $79,000. Finally, Magnetar Financial LLC bought a new stake in shares of Kura Oncology in the 1st quarter valued at $79,000.

Analyst Upgrades and Downgrades

Several research firms have issued reports on KURA. Wall Street Zen raised Kura Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 26th. JMP Securities reduced their price objective on Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating on the stock in a report on Monday, August 11th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Tuesday. Finally, Guggenheim started coverage on Kura Oncology in a report on Thursday, September 4th. They set a “neutral” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $24.10.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.